GlassScriptPhysician profile
Timothy Warren Damrow
NPI 1225418981
$9,965.33
in general payments reported to CMS, 2019-2025
42 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $1,524 · 2021: $1,518 · 2022: $1,410 · 2023: $1,032 · 2024: $1,978 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,735.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,479.67 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,366.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,134.63 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $858.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.51 | 2019-2025 | Jardiance |
| Amgen INC. | $389.55 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $338.27 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.49 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $307.70 | 2020-2025 | Spravato |
| Merck Sharp & Dohme LLC | $274.11 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $227.66 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $208.82 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $194.28 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $193.41 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $186.39 | 2021-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Damrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.